Table 3 Comparison of HbO values in various ROI areas among two groups of patients before treatment, at 2 weeks of treatment, and at 4 weeks of treatment (mmol*mm, \(\bar{x}\) ± s).

Group	Time point	n	Unaffected PMC	Affected PMC	Unaffected SMC	Affected SMC	Unaffected SMA	Affected SMA
Treatment group	T0	15	0.017 ± 0.021	0.011 ± 0.009	0.015 ± 0.014	0.012 ± 0.012	0.015 ± 0.015	0.007 ± 0.005
	T1	15	0.006 ± 0.005	0.016 ± 0.031	0.009 ± 0.005	0.007 ± 0.004	0.007 ± 0.006	0.012 ± 0.007
	T2	15	0.015 ± 0.016	0.019 ± 0.017^ac	0.018 ± 0.018	0.011 ± 0.009	0.014 ± 0.013	0.015 ± 0.012^b
Control group	T0	15	0.008 ± 0.006	0.008 ± 0.006	0.012 ± 0.008	0.011 ± 0.013	0.011 ± 0.012	0.006 ± 0.004
	T1	15	0.013 ± 0.010	0.009 ± 0.009	0.014 ± 0.016	0.012 ± 0.012	0.008 ± 0.007	0.014 ± 0.010
	T2	15	0.019 ± 0.012	0.007 ± 0.005	0.010 ± 0.007	0.012 ± 0.016	0.009 ± 0.005	0.015 ± 0.010

Intra-group comparison, treatment group after 4 weeks of treatment compared with before treatment, ^aP < 0.01, ^bP < 0.01; inter-group comparison, treatment group after 4 weeks of treatment compared with the control group after 4 weeks of treatment, ^cP < 0.01.

Quick links

Search